Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Total Current Liabilities: 2009-2025

Historic Total Current Liabilities for China Pharma Holdings (CPHI) over the last 16 years, with Sep 2025 value amounting to $6.6 million.

  • China Pharma Holdings' Total Current Liabilities rose 39.13% to $6.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.6 million, marking a year-over-year increase of 39.13%. This contributed to the annual value of $5.0 million for FY2024, which is 26.44% down from last year.
  • As of Q3 2025, China Pharma Holdings' Total Current Liabilities stood at $6.6 million, which was up 26.13% from $5.3 million recorded in Q2 2025.
  • China Pharma Holdings' 5-year Total Current Liabilities high stood at $12.7 million for Q4 2022, and its period low was $4.7 million during Q2 2024.
  • Moreover, its 3-year median value for Total Current Liabilities was $5.7 million (2024), whereas its average is $6.7 million.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first crashed by 55.32% in 2024, then soared by 39.13% in 2025.
  • China Pharma Holdings' Total Current Liabilities (Quarterly) stood at $10.5 million in 2021, then increased by 21.17% to $12.7 million in 2022, then crashed by 46.46% to $6.8 million in 2023, then dropped by 26.44% to $5.0 million in 2024, then spiked by 39.13% to $6.6 million in 2025.
  • Its last three reported values are $6.6 million in Q3 2025, $5.3 million for Q2 2025, and $5.1 million during Q1 2025.